Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Aryzta AG    ARYN   CH0043238366

ARYZTA AG

(ARYN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Novartis's Alcon spinoff ousts Baer from Swiss benchmark SMI

share with twitter share with LinkedIn share with facebook
share via e-mail
04/03/2019 | 05:46am EST
FILE PHOTO: Logo of Swiss pharmaceutical company Novartis is seen in Hueninge, France

ZURICH (Reuters) - Novartis's spinoff of its eyecare division Alcon, set for Tuesday April 9, marks the largest Swiss stock deal in a decade and forces a reshuffle of the benchmark Swiss Market Index (SMI) as private bank Julius Baer gets booted out.

Novartis has estimated Alcon's value at around 25 billion Swiss francs (19.06 billion pounds), while some analysts predict an initial market capitalisation of 21 billion francs ($21 billion) to 23 billion, implying shares worth from 43 to 47 francs.

By contrast Baer's value has tumbled by a third in a year to 9.3 billion francs. It will instead be included in the SMIM index, replacing Aryzta, SIX Swiss Exchange said after Tuesday's market close.

Dominated by Nestle, Novartis and Roche, the SMI is Switzerland's most important index. Membership is based on market capitalisation, adjusted for the free float of readily tradable shares in its constituents.

Alcon is being spun off in a one-for-five share deal announced by Novartis last June as it focuses on new drugs rather than the surgical devices and contact lenses Alcon makes.

Joining the SMI may boost demand from funds focusing on the top Swiss companies. Yet Alcon's inclusion means healthcare and medical technology will weigh even more heavily on the SMI.

Novartis's weighting had been capped 18 percent, but with Alcon the two will account for up to 21.5 percent of the SMI, Zuercher Kantonalbank analysts estimated on Wednesday.

Novartis's biggest owners - BlackRock, the Sandoz family, Capital Research Global Investors and Vanguard Group - will have similar holdings in Alcon, between 2.5 percent and 4.5 percent.

"We anticipate incremental buying of Alcon shares by some funds seeking to build a full-size position, offset by others not wanting to own a non-pharma eyecare company," Jefferies analyst Peter Welford said.

Novartis bought Alcon's eye surgery and contact lens portfolio in stages through 2010 for $52 billion from Nestle, only to see it lose ground to competitors as sales and profitability slipped.

In surgical equipment, Alcon competes against Johnson & Johnson, Germany's Zeiss and Bausch in a $9 billion per year market. Rivals in vision care, worth $14 billion annually, include J&J, Cooper and Bausch.

In 2016, a new Alcon head, Mike Ball from Hospira, redoubled research and marketing spending to resurrect revenue, before Novartis chief Vas Narasimhan decided to shed the division.

The last comparable-sized Swiss listing was in 2010, when oil driller Transocean floated on the same day its Deepwater Horizon rig exploded in the Gulf of Mexico.

(Editing by David Holmes)

By John Miller and Paul Arnold

Stocks mentioned in the article
ChangeLast1st jan.
ARYZTA AG -4.27% 0.9272 Delayed Quote.-10.48%
BAUSCH HEALTH COMPANIES INC. 0.23% 35.02 Delayed Quote.-10.11%
JOHNSON & JOHNSON 1.05% 149.93 Delayed Quote.2.10%
JULIUS BÄR GRUPPE -0.93% 47.91 Delayed Quote.-3.14%
NOVARTIS -0.17% 94.4 Delayed Quote.2.89%
SGS -0.38% 2634 Delayed Quote.-0.26%
SMI -0.39% 11110.78 Delayed Quote.4.99%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ARYZTA AG
01/23ARYZTA : announces the completion of the sale of the majority of its Picard stak..
AQ
01/14ARYZTA : Planned Organisational Changes ARYZTA North America
AQ
2019ARYZTA : Canada introduces Mette Munk, authentic Danish pastries, just in time f..
AQ
2019ARYZTA : Q1 2020 - Revenue in line with expectations
AQ
2019ARYZTA AG : 1st quarter results
CO
2019ARYZTA : AGM Result
AQ
2019ARYZTA : Proxy Statments
CO
2019ARYZTA : Notices
CO
2019ARYZTA : Crossing thresholds
CO
2019ARYZTA : Announcement by ARYZTA AG regarding the 2019 AGM
AQ
More news
Financials (EUR)
Sales 2020 3 358 M
EBIT 2020 184 M
Net income 2020 -240 M
Debt 2020 865 M
Yield 2020 -
P/E ratio 2020 -3,47x
P/E ratio 2021 146x
EV / Sales2020 0,53x
EV / Sales2021 0,50x
Capitalization 919 M
Chart ARYZTA AG
Duration : Period :
Aryzta AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ARYZTA AG
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 7
Average target price 0,97  €
Last Close Price 0,93  €
Spread / Highest target 51,4%
Spread / Average Target 4,71%
Spread / Lowest Target -31,3%
EPS Revisions
Managers
NameTitle
Kevin E. Toland Chief Executive Officer & Director
Gary W. McGann Chairman
Frédéric Pflanz Chief Financial Officer
Andrew Morgan Independent Non-Executive Director
Annette Flynn Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ARYZTA AG-10.48%976
FLOWERS FOODS, INC.2.16%4 699
YAMAZAKI BAKING CO., LTD.0.45%3 898
TOLY BREAD CO.,LTD.-4.01%3 822
MAYORA INDAH TBK PT--.--%3 230
HOSTESS BRANDS, INC.-9.28%1 595